Biocon
- Advice
- Hold
Biocon Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Biocon
Start SIPBiocon Investment Rating
-
Master Rating:
-
Biocon (Nse) has an operating revenue of Rs. 9,042.20 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 15% is great, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 47%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 51 which is a POOR score indicating inconsistency in earnings, a RS Rating of 11 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 157 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|
| Oper Rev Qtr Cr | 490 | 442 | 518 |
| Operating Expenses Qtr Cr | 462 | 439 | 491 |
| Operating Profit Qtr Cr | 28 | 3 | 27 |
| Depreciation Qtr Cr | 30 | 29 | 28 |
| Interest Qtr Cr | 0 | 0 | 0 |
| Tax Qtr Cr | 119 | 8 | 21 |
| Net Profit Qtr Cr | 988 | 15 | 38 |
Biocon Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 2
- Bearish Moving Average
- ___
- 14
- 20 Day
- 246.31
- 50 Day
- 257.95
- 100 Day
- 271.62
- 200 Day
- 293.29
- 20 Day
- 247.07
- 50 Day
- 261.45
- 100 Day
- 271.29
- 200 Day
- 298.46
Biocon Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 243.65 |
| Second Resistance | 247.6 |
| Third Resistance | 251.25 |
| RSI | 34.26 |
| MFI | 27.21 |
| MACD Single Line | -6.87 |
| MACD | -7.2 |
| Support | |
|---|---|
| First Resistance | 236.05 |
| Second Resistance | 232.4 |
| Third Resistance | 228.45 |
Biocon Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 1,720,359 | 60,797,487 | 35.34 |
| Week | 3,237,643 | 96,773,149 | 29.89 |
| 1 Month | 1,997,402 | 78,597,756 | 39.35 |
| 6 Month | 2,238,010 | 102,456,108 | 45.78 |
Biocon Result Highlights
Biocon Synopsis
NSE-Medical-Biomed/Biotech
Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1738.20 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2022. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.| Market Cap | 28,724 |
| Sales | 1,922 |
| Shares in Float | 46.82 |
| No of funds | 513 |
| Yield | 0.21 |
| Book Value | 3.55 |
| U/D Vol ratio | 0.6 |
| LTDebt / Equity | 1 |
| Alpha | -0.18 |
| Beta | 0.79 |
Biocon
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 60.64% | 60.64% | 60.64% | |
| Mutual Funds | 3.95% | 3.21% | 3.05% | |
| Insurance Companies | 4.68% | 4.55% | 4.25% | |
| Foreign Portfolio Investors | 14.42% | 15.79% | 16.31% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 12.47% | 12.07% | 10.72% | |
| Others | 3.84% | 3.74% | 5.03% |
Biocon Management
| Name | Designation |
|---|---|
| Mr. Siddharth Mittal | Managing Director & CEO |
| Ms. Kiran Mazumdar Shaw | Executive Chairperson |
| Mr. John Shaw | Vice Chairman & Non Exe.Dire |
| Prof. Ravi Mazumdar | Non Executive Director |
| Mr. Mary Harney | Independent Director |
| Mr. Daniel M Bradbury | Independent Director |
| Dr. Vijay Kuchroo | Independent Director |
| Mr. M Damodaran | Independent Director |
| Mr. Bobby Kanubhai Parikh | Independent Director |
Biocon Forecast
Price Estimates
About Company
Biocon FAQs
What is Share Price of Biocon ?
Biocon share price is ₹239 As on 03 February, 2023 | 05:28
What is the Market Cap of Biocon ?
The Market Cap of Biocon is ₹28724.4 Cr As on 03 February, 2023 | 05:28
What is the P/E ratio of Biocon ?
The P/E ratio of Biocon is 46.6 As on 03 February, 2023 | 05:28
What is the PB ratio of Biocon ?
The PB ratio of Biocon is 3 As on 03 February, 2023 | 05:28
Is it a good time to invest in Biocon Limited?
Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.
How many times has Biocon Limited given dividends since 2004?
Biocon Ltd. has declared 17 dividends since July 1, 2004.
What is the stock price CAGR of Biocon Limited?
The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.
What is the debt-to-equity ratio of Biocon Limited?
The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.
What is the ROE of the Biocon Limited?
The ROE of Biocon Limited is 9% which is fair but needs improvement.
Who is the Managing Director of Biocon Limited?
Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.
Is Biocon a good stock to buy?
According to the record analysis of moneyworks4me, Biocom limited is an average quality company.
What is the revenue of Biocon?
The revenue of Biocon for FY22 is Rs. 8184 Cr.
How to buy shares of Biocon Ltd?
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.